OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Xagena Salute

Search results for "Sorafenib"

A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow de ...


Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-val ...


Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...


Older and younger patients with renal cancer derive similar benefit from Sorafenib ( Nexavar ) therapy and tolerate the drug equally well. Although the risk of being diagnosed with cancer increa ...


A multi-institution team, funded by the National Human Genome Research Institute ( NHGRI ) of the National Institutes of Health ( NIH ), reported results of the largest effort to date to chart the gen ...


European Researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with Cetuximab ( Erbitux ) and Panitumumab ( Vectibix ...


Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failur ...


Sorafenib is used in patients with advanced renal-cell carcinoma ( RCC ) or hepatocellular cancer, and its application in other types of cancers is also undergoing extensive clinical assessment. ...


New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus ( RAD001 ) significantly delays cancer progression in patients with m ...


Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...


Use of Lapatinib ( Tykerb ) to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While ...


In the advanced breast cancer, one study has found that if Sorafenib ( Nexavar ) is combined with the chemotherapy drug, Capecitabine ( Xeloda ), it makes a significant difference to the time women li ...


The cancer drug Sorafenib ( Nexavar ) holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial.If approved for use in thyroid ...


Bayer HealthCare and Onyx Pharmaceuticals, have announced that the FDA ( Food and Drug Administration ) has approved the oral multi-kinase inhibitor Nexavar ( Sorafenib ) for the treatment of patients ...


An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor ( FGF ) pathway activation ha ...